CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo

Thus far the clinical benefits seen in breast cancer patients treated with drugs targeting the vascular endothelial growth factor (VEGF) pathway are only modest. Consequently, additional antiangiogenic approaches for treatment of breast cancer need to be investigated. Thrombospondin-2 (TSP-2) has been shown to inhibit tumor growth and angiogenesis with a greater potency than the related molecule TSP-1. The systemic effects of TSP-2 on tumor metastasis and the underlying molecular mechanisms of the antiangiogenic activity of TSP-2 have remained poorly understood. We generated a recombinant fusion protein consisting of the N-terminal region of TSP-2 and the IgG-Fc1 fragment (N-TSP2-Fc) and could demonstrate that the antiangiogenic activity of N-TSP2-Fc is dependent on the CD36 receptor. We found that N-TSP2-Fc inhibited VEGF-induced tube formation of human dermal microvascular endothelial cells (HDMEC) on matrigel in vitro and that concurrent incubation of anti-CD36 antibody with N-TSP2-Fc resulted in tube formation that was comparable to untreated control. N-TSP2-Fc potently induced apoptosis of HDMEC in vitro in a CD36-dependent manner. Moreover, we could demonstrate a CD36 receptor-mediated loss of mitochondrial membrane potential and activation of caspase-3 in HDMEC in vitro. Daily intraperitoneal injections of N-TSP2-Fc resulted in a significant inhibition of the growth of human MDA-MB-435 and MDA-MB-231 tumor cells grown in the mammary gland of immunodeficient nude mice and in reduced tumor vascularization. Finally, increased serum concentrations of N-TSP2-Fc significantly inhibited regional metastasis to lymph nodes and distant metastasis to lung as shown by quantitative real-time alu PCR. These results identify N-TSP2-Fc as a potent systemic inhibitor of tumor metastasis and provide strong evidence for an important role of the CD36 receptor in mediating the antiangiogenic activity of TSP-2.

[1]  M. Detmar,et al.  Thrombospondin‐2 plays a protective role in multistep carcinogenesis: a novel host anti‐tumor defense mechanism , 2001, The EMBO journal.

[2]  Andries Zijlstra,et al.  A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction. , 2002, Cancer research.

[3]  M. Detmar,et al.  Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Josephine C. Adams,et al.  The thrombospondins. , 2011, Cold Spring Harbor perspectives in biology.

[5]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[6]  R. Silverstein,et al.  The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. , 2005, Matrix biology : journal of the International Society for Matrix Biology.

[7]  J. Lawler.  The functions of thrombospondin-1 and-2. , 2000, Current opinion in cell biology.

[8]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[9]  J. Price,et al.  Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. , 1990, Cancer research.

[10]  F. Marincola,et al.  Quantitative real-time PCR: a powerful ally in cancer research. , 2003, Trends in molecular medicine.

[11]  G. Tuszynski,et al.  Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor , 2000, British Journal of Cancer.

[12]  M. Olivé,et al.  Breast tumor cell lines from pleural effusions. , 1974, Journal of the National Cancer Institute.

[13]  J Folkman,et al.  Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.

[14]  D. Welch.  Technical considerations for studying cancer metastasis in vivo , 1997, Clinical & Experimental Metastasis.

[15]  P. Bornstein,et al.  Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. , 2001, The American journal of pathology.

[16]  J. Lawler,et al.  The effect of thrombospondin-1 on breast cancer metastasis , 2009, Breast Cancer Research and Treatment.

[17]  S. Goodison,et al.  Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  A. Chambers,et al.  MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? , 2009, Cancer research.

[19]  H. Krutzsch,et al.  Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin‐binding domain and synthetic peptides from the type I repeats of thrombospondin , 1993, Journal of cellular biochemistry.

[20]  O. Volpert,et al.  Inhibition of angiogenesis by thrombospondin-2. , 1995, Biochemical and biophysical research communications.

[21]  I Nicoletti,et al.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. , 1991, Journal of immunological methods.

[22]  Christian A. Rees,et al.  Systematic variation in gene expression patterns in human cancer cell lines , 2000, Nature Genetics.

[23]  A. Patchefsky,et al.  Primary combined malignant melanoma and ductal carcinoma of the breast: A report of two cases , 1996, Cancer.

[24]  W. Scheuer,et al.  Quantification of human Alu sequences by real-time PCR – an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants , 2004, Clinical & Experimental Metastasis.

[25]  M. Iruela-Arispe,et al.  Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. , 1999, Circulation.

[26]  A. Hollestelle,et al.  Comment Re: MDA-MB-435 and M14 cell lines: identical but not M14 Melanoma? , 2009, Cancer research.

[27]  J. Roth,et al.  Production of melanoma-associated antigen(s) by a defined malignant melanoma cell strain grown in chemically defined medium. , 1976, Cancer research.

[28]  K. Pantel,et al.  Current status in human breast cancer micrometastasis , 2007, Current opinion in oncology.

[29]  H. Krutzsch,et al.  Regulation of Transforming Growth Factor-β Activation by Discrete Sequences of Thrombospondin 1 (*) , 1995, The Journal of Biological Chemistry.

[30]  H. Allgayer,et al.  TaqMan-based quantification of invasive cells in the chick embryo metastasis assay. , 2004, BioTechniques.

[31]  P. Steeg,et al.  Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. , 1994, Cancer research.

[32]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[33]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[34]  Hans Clevers,et al.  Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines , 2010, Breast Cancer Research and Treatment.

[35]  O. Volpert,et al.  Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. , 1999, Molecular pharmacology.

[36]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[37]  A. Giuliano,et al.  Detection of Circulating Tumor Cells in Early-Stage Breast Cancer Metastasis to Axillary Lymph Nodes , 2007, Clinical Cancer Research.

[38]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[39]  O. Volpert,et al.  Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 , 2000, Nature Medicine.

[40]  O. Volpert,et al.  Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity , 1993, The Journal of cell biology.

[41]  E. Ginns,et al.  Mice That Lack Thrombospondin 2 Display Connective Tissue Abnormalities That Are Associated with Disordered Collagen Fibrillogenesis, an Increased Vascular Density, and a Bleeding Diathesis , 1998, The Journal of cell biology.

[42]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[43]  M. Granick,et al.  Thrombospondin and transforming growth factor‐beta 1 increase expression of urokinase‐type plasminogen activator and plasminogen activator inhibitor‐1 in human MDA‐MB‐231 breast cancer cells , 1995, Cancer.

[44]  R. Hynes,et al.  Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. , 1998, The Journal of clinical investigation.

[45]  Gordon B Mills,et al.  Lineage Infidelity of MDA-MB-435 Cells , 2004, Cancer Research.

[46]  M. Corada,et al.  Endothelial cell‐to‐cell junctions , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  R. Burgeson,et al.  A Novel Member of the Netrin Family, β-Netrin, Shares Homology with the β Chain of Laminin , 2000, The Journal of cell biology.

[48]  Thomas Hawighorst,et al.  Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis , 2001, Nature Medicine.

[49]  D. Berger,et al.  Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system. , 1997, Surgery.

[50]  J. Lawler,et al.  Thrombospondins: from structure to therapeutics , 2008, Cellular and Molecular Life Sciences.

[51]  Chad J. Creighton,et al.  MDA-MB-435 cells are derived from M14 Melanoma cells––a loss for breast cancer, but a boon for melanoma research , 2007, Breast Cancer Research and Treatment.

[52]  K. Matsuda,et al.  An N-terminal 80 kDa recombinant fragment of human thrombospondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo. , 2003, The Journal of investigative dermatology.

[53]  S. Futagawa,et al.  Breast carcinoma diverging to aberrant melanocytic differentiation: a case report with histopathologic and loss of heterozygosity analyses. , 1999, The American journal of surgical pathology.

[54]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[55]  David W. Dawson,et al.  CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells , 1997, The Journal of cell biology.